GENOMEFRONTIER THERAPEUTICS
GenomeFrontier Therapeutics is committed to developing state-of-the-art products and platforms for the production of next-generation gene-modified cell therapies that are safe, effective, specific, and persistent, thus generating a robust immune response that can eradicate diseases.
GENOMEFRONTIER THERAPEUTICS
Industry:
Biotechnology Health Care Personal Health Therapeutics
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.genomefrontier.com
Total Employee:
11+
Status:
Active
Contact:
+886 2 2655 8766
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome
Official Site Inspections
http://www.genomefrontier.com
- Host name: 53.138.153.160.host.secureserver.net
- IP address: 160.153.138.53
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "GenomeFrontier Therapeutics"
Home - GenomeFrontier Therapeutics, Inc. ๅ ้ฉ ็ๆ
Using the Quantum Engineโข, GenomeFrontier is developing multiple cell modified gene therapy products, including chimeric antigen receptor T (CAR T) and T cell receptor T (TCR T) therapies. These are live, cell-based โdrugsโ โฆSee details»
GenomeFrontier Therapeutics - Crunchbase Company Profile
Organization. GenomeFrontier Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... GenomeFrontier Therapeutics is โฆSee details»
GenomeFrontier Therapeutics, Inc. | LinkedIn
GenomeFrontier Therapeutics, Inc. | 139 followers on LinkedIn. Innovation for HumanitySee details»
GenomeFrontier Therapeutics - Overview, News & Similar
Currently, GenomeFrontier Therapeutics Inc. has a number of CAR-T and TCR-T cell products for cancer treatment that are undergoing development using the Quantum Engineโข. Read more. โฆSee details»
ๅ ้ฉ ็ๆ่กไปฝๆ้ๅ ฌๅธ๏ฝๅพตๆไธญ๏ผ104ไบบๅ้่ก
Key Responsibilities: โข Strategic Planning & Execution o Develop and execute comprehensive business development strategies to expand GenomeFrontier's market presence in the cell โฆSee details»
[TRPMA Member] GenomeFrontier Therapeutics, Inc.
Jul 12, 2018 GenomeFrontier Therapeutics, Inc. (GF), established in 2018, leverages our non-viral based gene and cell engineering technologies to create immunotherapies for the โฆSee details»
Genomefrontier Therapeutics, Inc. - Drug pipelines, Patents, โฆ
Explore Genomefrontier Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Neoplasms, Immune System Diseases, Hemic and ...See details»
Company - GenomeFrontier Therapeutics, Inc. ๅ ้ฉ ็ๆ
G enomeFrontier is an innovation-driven therapeutic company, focusing on the development of next-generation gene therapies. Striving to reach the pinnacle in the field of gene therapy, we โฆSee details»
GenomeFrontier Therapeutics - VentureRadar
Using the Quantum Engineโข, GenomeFrontier is developing multiple cell modified gene therapy products, including chimeric antigen receptor T (CAR-T) and T cell receptor T (TCR-T) โฆSee details»
GenomeFrontier Selects BioCina to Manufacture Minicircle and โฆ
ADELAIDE, Australia, Oct. 17, 2023 /PRNewswire/ โ BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new โฆSee details»
GenomeFrontier Therapeutics - Contacts, Employees, Board โฆ
GenomeFrontier Therapeutics develops gene-modified cell therapy. Start Free TrialSee details»
GenomeFrontier and BioCina partner on CAR-T Therapy Product
Oct 16, 2023 GenomeFrontier (GF) is an innovation-driven therapeutics company focusing on the development of next-generation virus-free gene therapies. Addressing the limitations of โฆSee details»
Our Mission - GenomeFrontier Therapeutics, Inc. ๅ ้ฉ ็ๆ
Our mission is to develop innovative gene therapies and cell therapies that are affordable and therapeutically effective.See details»
GenomeFrontier Therapeutics' Non-Viral CAR-T Therapy Moves to โฆ
Feb 15, 2025 In 2006, Dr. Sareina Chiung-Yuan Wu, founder of GenomeFrontier Therapeutics, discovered the potential of piggyBac as a gene vector. This breakthrough led to the founding โฆSee details»
GenomeFrontier Selects BioCina to Manufacture Minicircle and โฆ
Oct 17, 2023 GenomeFrontier's founder and CEO/CSO, Sareina Wu said, "We believe that a cancer-free world is not only possible but is more real than ever before, due to major โฆSee details»
GenomeFrontier Selects BioCina to Manufacture Minicircle and
ADELAIDE, Australia, Oct. 17, 2023 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new โฆSee details»
BioCina and Genome Frontier Tie Up - BioProcess Insider
Oct 23, 2023 Contract development and manufacturing organization (CDMO), BioCina aims to support GenomeFrontier with development and GMP manufacturing for minicircle DNA โฆSee details»
Quantum Engine - GenomeFrontier Therapeutics, Inc. ๅ ้ฉ ็ๆ
GenomeFrontier is committed to develop state-of-the-art products and platforms for production of next-generation gene-modified cell therapies that are highly effective, specific, persistent, and โฆSee details»
First-in-Canada genomics platform to support greater access to ...
1 day ago OICR Genomics is running the countryโs first Ultima UG 100 sequencing platform. By bringing the latest genomic sequencing technology to Ontario, OICR is boosting the provinceโs โฆSee details»
Pipeline - GenomeFrontier Therapeutics, Inc. ๅ ้ฉ ็ๆ
GF-CART01: a dual targeting, safety switch-equipped CAR T therapy for treatment of B cell malignancies; GF-CART02: a dual targeting, safety switch-equipped CAR T therapy for โฆSee details»